Cite
HARVARD Citation
Yanagisawa, T. et al. (2022). Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high‐risk metastatic hormone‐sensitive prostate cancer. Prostate. 82 (1), pp. 3-12. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Yanagisawa, T. et al. (2022). Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high‐risk metastatic hormone‐sensitive prostate cancer. Prostate. 82 (1), pp. 3-12. [Online].